Exhibit 99.1 Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights - Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 - CARLSBAD, Calif., November 5, 2025 – Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the thir ...